Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $212.5 million.

  • Beam Therapeutics' Non-Current Assets fell 5.89% to $212.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year decrease of 5.89%. This contributed to the annual value of $225.7 million for FY2024, which is 9.25% down from last year.
  • As of Q3 2025, Beam Therapeutics' Non-Current Assets stood at $212.5 million, which was down 1.46% from $215.7 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Non-Current Assets ranged from a high of $259.1 million in Q2 2023 and a low of $178.7 million during Q1 2021.
  • For the 3-year period, Beam Therapeutics' Non-Current Assets averaged around $234.3 million, with its median value being $231.8 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 230.16% in 2021, then declined by 10.52% in 2024.
  • Beam Therapeutics' Non-Current Assets (Quarterly) stood at $201.4 million in 2021, then increased by 23.52% to $248.8 million in 2022, then declined by 0.06% to $248.7 million in 2023, then declined by 9.25% to $225.7 million in 2024, then dropped by 5.89% to $212.5 million in 2025.
  • Its Non-Current Assets was $212.5 million in Q3 2025, compared to $215.7 million in Q2 2025 and $219.3 million in Q1 2025.